AOD-9604

AOD-9604 is a modified fragment of human growth hormone (hGH amino acids 177-191) with an N-terminal tyrosine, developed by Professor Frank Ng at Monash University in collaboration with Metabolic Pharmaceuticals Ltd (Australia). It stimulates lipolysis and inhibits lipogenesis through beta-3 adrenergic receptor upregulation without the growth-promoting effects of full hGH. Six clinical trials enrolling ~900 participants demonstrated excellent safety but the pivotal Phase IIb trial failed to show clinically meaningful weight loss, leading to development termination in 2007. Australia's TGA has approved it as iTRAM for intra-articular knee osteoarthritis. It is not FDA-approved and is WADA-prohibited.

• Fat Loss / Lipolysis
• Lipogenesis Inhibition
• Metabolic Safety

Stimulates fat loss through lipolysis without growth hormone side effects. Does not increase IGF-1, affect glucose metabolism, or cause insulin resistance. Also shows promise for cartilage repair. Note: subcutaneous injection is community-derived — all six clinical trials used oral dosing.

AOD-9604 acts through a dual mechanism: acutely, it stimulates lipolysis and energy expenditure through receptor-independent pathways; chronically, it upregulates beta-3 adrenergic receptor (β3-AR) expression in adipose tissue (restoring levels to lean-equivalent) to sustain fat oxidation. This was confirmed by knockout mouse studies where acute effects persisted but chronic weight loss was abolished without β3-AR. Crucially, it does not bind the GH receptor, does not increase IGF-1, and does not cause hyperglycemia or cell proliferation.

Peak plasma concentration: 15 min. Elimination half-life: 30 min. Largely cleared by: ~2.5 hrs.

Research protocols from published literature — not dosing recommendations.

• Hyaluronic Acid — Synergistic: Research shows combined AOD-9604 and HA injections are more effective for cartilage repair than either alone.
• BPC-157 — Compatible: Different mechanisms of action. Sometimes combined in regenerative protocols.
• CJC-1295 — Compatible: AOD-9604 does not affect GH axis, allowing combination with GH secretagogues.
• Ipamorelin — Compatible: No known interactions. Different mechanisms - can be used together.
• Semaglutide — Compatible: Different fat loss mechanisms. May have complementary effects on weight management.
• Insulin — Compatible: AOD-9604 does not affect glucose metabolism or insulin sensitivity unlike full hGH.

Supplies:

• Lyophilized AOD-9604 peptide vial
• Bacteriostatic water (BAC water)
• Insulin syringes (0.5-1mL)
• Alcohol swabs
• Sterile work surface

1. 1Allow vial to reach room temperature (15-20 minutes)
2. 2Calculate required BAC water volume using calculator below
3. 3Draw BAC water into syringe
4. 4Inject slowly down vial side (not directly onto powder)
5. 5Gently swirl until dissolved (never shake vigorously)
6. 6Store reconstituted solution at 2-8°C and use within 28 days

Week 1-2: Minimal noticeable effects, compound building in system. Week 3-4: May notice subtle changes in body composition. Week 5-8: More noticeable fat loss, especially with diet and exercise. Week 8-12: Continued fat reduction, improved body composition. Side effects: Generally well-tolerated, mild injection site reactions possible.

Excellent safety in 6 RCTs (~900 participants) — zero serious adverse events, profile indistinguishable from placebo. 158,989 US compounding prescriptions filled with zero FDA FAERS adverse event reports (as of 2024). Does not affect blood glucose, insulin, or IGF-1 — safer metabolic profile than full hGH. No anti-AOD-9604 antibodies detected in any trial participant. May cause mild injection site reactions. Not recommended during pregnancy or breastfeeding. WADA prohibited substance — banned at all times under S.0 category. Long-term safety beyond 24 weeks has not been studied. FDA recommended against 503A bulks list inclusion in Dec 2024 citing immunogenicity concerns.

Excellent safety in 6 RCTs (~900 participants) — zero serious adverse events, profile indistinguishable from placebo. 158,989 US compounding prescriptions filled with zero FDA FAERS adverse event reports (as of 2024). Does not affect blood glucose, insulin, or IGF-1 — safer metabolic profile than full hGH. No anti-AOD-9604 antibodies detected in any trial participant. May cause mild injection site reactions. Not recommended during pregnancy or breastfeeding. WADA prohibited substance — banned at all times under S.0 category. Long-term safety beyond 24 weeks has not been studied. FDA recommended against 503A bulks list inclusion in Dec 2024 citing immunogenicity concerns.

AOD-9604 should be stored at Lyophilized: room temp short-term, freezer long-term. Reconstituted: 2-8°C for 28 days.